Reality Check on Cystic Fibrosis
Market access for cystic fibrosis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Increasing restrictions for lives covered under medicare, payer-controlled pharmacy benefit
- Class Trends: Why CF patient adherence is fueling investment and correlation to the flood of new treatments over coming years
- Key Findings: Complex reimbursement affects all products, new and old, in nearly all geographies
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.